(Q36837061)

16 August 2017

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml (English)

1 reference

16 August 2017

1 reference

Yu-Hsuan Shao

1

1 reference

16 August 2017

Peter C Albertsen

2

1 reference

16 August 2017

Calpurnyia B Roberts

3

1 reference

16 August 2017

Yong Lin

4

1 reference

16 August 2017

Amit R Mehta

5

1 reference

16 August 2017

Mark N Stein

6

1 reference

16 August 2017

Robert S DiPaola

7

1 reference

16 August 2017

Grace L Lu-Yao

8

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

16 August 2017

JAMA Internal Medicine

1 reference

16 August 2017

170

1 reference

16 August 2017

1256-1261

1 reference

16 August 2017

14

1 reference

Screening and prostate-cancer mortality in a randomized European study

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Survival following primary androgen deprivation therapy among men with localized prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

29 September 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Quality of life after radical prostatectomy or watchful waiting.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3651841

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

5 September 2018

1 reference

12 December 2020

Survival associated with treatment vs observation of localized prostate cancer in elderly men

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study

1 reference

12 December 2020

Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?

1 reference

12 December 2020

It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

1 reference

12 December 2020

10.1001/ARCHINTERNMED.2010.221

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

1 reference